Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory bowel disease: medical cost algorithms.

A R Hay1, J W Hay

  • 1Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles 90033.

Journal of Clinical Gastroenterology
|June 1, 1992
PubMed
Summary

Inflammatory bowel disease (IBD) medical costs are substantial, with surgery and inpatient care comprising half of expenses. Crohn's disease costs $6,561 annually per patient, while ulcerative colitis costs $1,488.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2013
Same author

Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2009
Same author

Using pharmacoeconomics to value pharmacotherapy.

Clinical pharmacology and therapeutics·2008
Same author

Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.

Rheumatology (Oxford, England)·2007
Same author

Economic burden of haematological adverse effects in cancer patients: a systematic review.

Clinical drug investigation·2007

Area of Science:

  • Gastroenterology
  • Health Economics

Background:

  • Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), presents significant healthcare burdens.
  • Accurate medical cost estimation is crucial for resource allocation and healthcare policy development.

Purpose of the Study:

  • To estimate the medical costs associated with Crohn's disease and ulcerative colitis in the U.S. using a literature-based costing methodology.
  • To identify the primary cost drivers within IBD patient care.

Main Methods:

  • A literature-based medical decision algorithm costing methodology was employed.
  • Cost data were analyzed for different components of care, including surgery, inpatient stays, outpatient services, diagnostics, and medications.

Main Results:

Related Experiment Videos

  • Surgery and inpatient care accounted for approximately 50% of total IBD medical costs.
  • Average annual medical costs were estimated at $6,561 for Crohn's disease and $1,488 for ulcerative colitis (1990 USD).
  • Total U.S. annual medical costs for IBD in 1990 were estimated at $1.0-1.2 billion for CD and $0.4-0.6 billion for UC.

Conclusions:

  • IBD imposes a substantial economic burden, with significant costs attributed to inpatient and surgical interventions.
  • Understanding cost breakdowns is essential for developing targeted cost-containment strategies in IBD management.